WEIGHT LOSS

Semaglutide, a GLP-1 agonist, is FDA-approved as Ozempic and Rybelsus for type 2 diabetes management and as Wegovy for overweight and obesity treatment. At higher doses, it aids fat loss by suppressing appetite. When paired with a healthy diet and exercise, semaglutide shows impressive results and has been used by healthcare providers for over 15 years in diabetes management.

Retatrutide, a new medication developed by Eli Lilly, shows significant promise for treating obesity and diabetes. Also referred to as the GGG tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable treatment is similar to current weight loss medications like tirzepatide and semaglutide but offers enhanced efficacy. When paired with a healthy diet, regular exercise, and lifestyle changes, retatrutide can improve weight loss results and address obesity-related comorbidities such as diabetes and hypertension.

Liraglutide is primarily used to treat type 2 diabetes and obesity. It promotes the release of insulin, a hormone that helps lower blood sugar levels. The greater the amount of insulin the pancreas produces, the less likely blood sugar levels are to surge. Additionally, there is growing evidence indicating that this medication may provide other health advantages.

Tirzepatide, a dual GIP and GLP-1 receptor agonist from Eli Lilly, treats type 2 diabetes, obesity, and non-alcoholic fatty liver disease. Approved by the ADA and FDA in May 2022, it is administered via subcutaneous injection using a pre-filled pen or syringe.

Researchers are exploring its potential for heart failure, obstructive sleep apnea, non-alcoholic steatohepatitis, chronic kidney disease, and its effects on obesity-related health.